Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma
- Supplementary File 1:
ZIP-Document (ZIP, 99777 KiB)
Kamoto, S.; Shinada, M.; Kato, D.; Yoshimoto, S.; Ikeda, N.; Tsuboi, M.; Yoshitake, R.; Eto, S.; Hashimoto, Y.; Takahashi, Y.; Chambers, J.; Uchida, K.; Kaneko, M.K.; Fujita, N.; Nishimura, R.; Kato, Y.; Nakagawa, T. Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma. Cells 2020, 9, 2529. https://doi.org/10.3390/cells9112529
Kamoto S, Shinada M, Kato D, Yoshimoto S, Ikeda N, Tsuboi M, Yoshitake R, Eto S, Hashimoto Y, Takahashi Y, Chambers J, Uchida K, Kaneko MK, Fujita N, Nishimura R, Kato Y, Nakagawa T. Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma. Cells. 2020; 9(11):2529. https://doi.org/10.3390/cells9112529
Chicago/Turabian StyleKamoto, Satoshi; Shinada, Masahiro; Kato, Daiki; Yoshimoto, Sho; Ikeda, Namiko; Tsuboi, Masaya; Yoshitake, Ryohei; Eto, Shotaro; Hashimoto, Yuko; Takahashi, Yosuke; Chambers, James; Uchida, Kazuyuki; Kaneko, Mika K.; Fujita, Naoki; Nishimura, Ryohei; Kato, Yukinari; Nakagawa, Takayuki. 2020. "Phase I/II Clinical Trial of the Anti-Podoplanin Monoclonal Antibody Therapy in Dogs with Malignant Melanoma" Cells 9, no. 11: 2529. https://doi.org/10.3390/cells9112529